HOUSTON, October 19, 2026 — Researchers at The University of Texas MD Anderson Cancer Center unveiled a sweeping collection of new findings spanning the full arc of modern oncology, offering fresh insight into lung and prostate cancer treatments.
Advancing Lung Cancer Immunotherapy
The global Phase 3 HARMONi trial tested a novel bispecific immunotherapy called ivonescimab in patients with EGFR-mutant non-small cell lung cancer, according to findings published in The Lancet Oncology. Patients receiving ivonescimab plus chemotherapy were 48 percent less likely to experience cancer progression or death than those receiving chemotherapy alone.
Trial co-lead Xiuning Le noted that treatment options after progression for EGFR-targeted therapies are limited, making these combination results an important new option for patients facing inevitable resistance. Early findings suggest that adding this bispecific immunotherapy to standard chemotherapy extends disease control while maintaining a manageable safety profile.
Uncovering Prostate Tumor Defense Mechanisms
A second study in Cancer Discovery revealed that the immune checkpoint molecule B7-H3 plays a dual role in castration-resistant prostate cancer. Researchers Di Zhao and Nicholas Navin found that B7-H3 reshapes the tumor microenvironment to help cancer grow and resist treatment, functioning as a backup physical defense. The encouraging part of this laboratory discovery is that combining a B7-H3-targeted therapy with MEK inhibition improved antitumor responses and prolonged survival in preclinical models.
Translating Laboratory Discoveries
These studies illustrate the institution’s strategy of translating laboratory discoveries into direct bedside care, addressing how to overcome drug resistance. While these breakthroughs offer renewed hope, patients should discuss all treatment decisions with their medical team. Talk to your doctor to understand how these emerging clinical options relate to individual care plans.
Targeting DNA Repair Weaknesses
Beyond immunotherapy, MD Anderson researchers are exploring synthetic lethality to exploit fundamental DNA repair vulnerabilities in cancer cells. A notable advancement involves VVD-133214, formerly known as RO7589831, which serves as the first clinical-stage covalent inhibitor of Werner helicase tested in humans. Many tumors rely heavily on this specific DNA repair enzyme to fix breaks in their genetic material, particularly when other redundant repair pathways are already defective. By covalently locking onto the helicase, the drug disables a critical molecular lifeline that cancer cells cannot afford to lose, even though normal cells can tolerate its absence.
In a Phase 1 trial published in Nature Medicine, the compound demonstrated promising, durable antitumor activity and remained generally well tolerated by patients. Timothy Yap, professor of Investigational Cancer Therapeutics and vice president and head of clinical development in the Therapeutics Discovery division, noted that the data validates Werner helicase as an actionable target. Because this patient population currently faces limited treatment options, the efficacy observed in early testing is significant. The program suggests that the logic of synthetic lethality—targeting vulnerabilities created by pre-existing tumor defects—can be extended to a fresh class of DNA repair dependencies. Larger trials are required to determine if these early durable responses will translate into future regulatory progress.
Blood Tests to Spare Unnecessary Chemotherapy
Researchers at MD Anderson are developing blood tests that could identify patients who may safely avoid chemotherapy, according to the source material. These tests aim to reduce overtreatment by pinpointing individuals unlikely to benefit from toxic therapies. The approach aligns with the institution’s broader strategy of personalizing cancer care through biomarker-driven decisions.
By analyzing circulating tumor DNA or other blood-based markers, clinicians could better predict treatment response before initiating therapy. This method supports efforts to manage side effects while maintaining effective cancer control. The goal is to spare patients from unnecessary toxicity when alternative, less aggressive options may be sufficient.
Sources
- MD Anderson Unveils Wave of Cancer Breakthroughs From Lung Immunotherapy to
- From radioactive tiles to AI maps: MD Anderson unveils five cancer advances
- Paper touted by MD Anderson gets expression of concern for data ‘concerns’
Photo: Kenneth C. Zirkel (CC BY 4.0)
